Latest News

Category: Clinical

See all

Telix Announces Positive Topline Results of ZIRCON Phase III Kidney Cancer Imaging Study

ASX, Clinical, News,

Telix today announces preliminary data from two separate investigator-initiated studies of TLX250-CDx (89Zr-DFO-girentuximab) in triple negative breast cancer (TNBC) and non-muscle-invasive bladder cancer (NMIBC), part of a comprehensive series of studies evaluating CAIX expression in cancers other than clear cell renal cell carcinoma (ccRCC), supporting Telix’s goal to rapidly expand the CAIX program into other indications beyond kidney...

Read more

Telix Recognised as Company of the Year at AusBiotech and Johnson & Johnson Innovation Industry Excellence Awards 2022

Clinical, News,

Telix is today pleased to announce that it has been awarded Australian Company of the Year in the 2022 AusBiotech and Johnson & Johnson Innovation Industry Excellence Awards, held today...

Read more

Telix and UniQuest to Collaborate on Radiolabelled Immune Targeting Peptide

Clinical, News,

Telix today announces a collaboration with UniQuest Pty Ltd (UniQuest), the commercialisation company of The University of Queensland (UQ), to develop a radiolabelled molecule targeting an immune checkpoint protein. The...

Read more

TLX250-CDx Indication Expansion: Preliminary Data Presented at EANM

ASX, Clinical, News,

Telix today announces preliminary data from two separate investigator-initiated studies of TLX250-CDx (89Zr-DFO-girentuximab) in triple negative breast cancer (TNBC) and non-muscle-invasive bladder cancer (NMIBC), part of a comprehensive series of...

Read more

First Patient Enrolled in ProstACT TARGET Study

ASX, Clinical, News,

Telix and GenesisCare, the largest provider of integrated cancer care in Australia, today announce that a first patient has been enrolled in the Phase II ProstACT TARGET study of Telix’s...

Read more

Final IPAX-1 Study Data Confirms Safety and Tolerability Profile for TLX101, Preliminary Efficacy Data

ASX, Clinical, News,

Telix today reports the final results from the IPAX-1 Ph I/II study of TLX101 therapy (4-L-[ ¹³¹I] iodo-phenylalanine, or ¹³¹I-IPA) in combination with external beam radiation therapy (EBRT) in recurrent...

Read more

Targeted Alpha Therapy Candidate: Bladder Cancer Study Completes Enrolment

ASX, Clinical, News,

Telix and Nantes-based ATONCO S.A.S. (‘ATONCO’) today announced that the final patient has been dosed in a Phase I study of TLX250-CDx in patients with non-muscle invasive bladder cancer (NMIBC)...

Read more

APAC Report: Regulatory Progress for Prostate and Kidney Cancer Imaging

ASX, Clinical, News,

Telix today reports on regulatory progress for the Company’s core prostate and kidney cancer imaging programs in the Asia Pacific (APAC) Operating Region, including progress in the major market of...

Read more

BAMF Health and Telix complete first total-body PET scans with Illuccix for prostate cancer imaging

Clinical, News,

Telix and BAMF Health use Illuccix® for the first time with uEXPLORER® total-body PET scanner for prostate cancer...

Read more